Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: Hepatic deterioration links to portosystemic shunt syndrome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 6, 2010, Pages 1129-1135

  Kumamoto, Masafumi ^a   Toyonaga, Atsushi ^b   Inoue, Hiroto ^a   Miyakoda, Kenji ^a   Morita, Yukihiko ^a   Emori, Keigo ^a   Sakamoto, Yoshihiro ^a   Oho, Kazuhiko ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yasumoto Hospital   (Japan)

Author keywords

Balloon occluded retrograde transvenous obliteration; Gastric fundal varices; Portosystemic shunt syndrome

Indexed keywords

ALBUMIN; BILIRUBIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BALLOON; BALOON OCCLUDED RETROGRADE TRANSVENOUS OBLITERATION; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SPONTANEOUS PORTOSYSTEMIC SHUNT; STOMACH VARICES; SURVIVAL RATE; VEIN OCCLUSION; AGED; ARTIFICIAL EMBOLISM; BALLOON OCCLUSION; BIOPSY; CATHETERIZATION; CAUSE OF DEATH; COLLATERAL CIRCULATION; COMPARATIVE STUDY; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; HEPATIC ENCEPHALOPATHY; LIVER; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PROCEDURES; RETROSPECTIVE STUDY; STOMACH FUNDUS; SYNDROME; TIME; TREATMENT OUTCOME; TRENDS; VASCULARIZATION; ABDOMINAL DISCOMFORT; BALLOON OCCLUDED RETROGRADE TRANSVENOUS OBLITERATION; BLEEDING; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; FEVER; HEMOGLOBINURIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; NONSURGICAL INVASIVE THERAPY; PORTOSYSTEMIC SHUNT SYNDROME; SPLENORENAL SHUNT SYNDROME; STATISTICAL ANALYSIS; VASCULAR DISEASE;

AGED; BALLOON OCCLUSION; BIOPSY; CATHETERIZATION, PERIPHERAL; CAUSE OF DEATH; COLLATERAL CIRCULATION; EMBOLIZATION, THERAPEUTIC; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTRIC FUNDUS; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952988989     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06262.x     Document Type: Article

References (49)

1. Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K. Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology 1988 95 : 434 440.
2. Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J. Gastroenterol. Hepatol. 1996 11 : 51 8.
3. Koito K, Namieno T, Nagakawa T, Morita K. Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals. AJR Am. J. Roentgenol. 1996 167 : 1317 1320.
4. Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology 1999 211 : 349 356.
5. Kitamoto M, Imamura M, Kamada K et al. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage. AJR Am. J. Roentgenol. 2002 178 : 1167 1174.
6. Choi YH, Yoon CJ, Park J, Chung JW, Kwon JW, Choi GM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J. Radiol. 2003 4 : 109 116.
7. Arai H, Abe T, Shimoda R, Takagi H, Yamada T, Mori M. Emergency balloon-occluded retrograde transvenous obliteration for gastric varices. J. Gastroenterol. 2005 40 : 964 971.
8. Ninoi T, Nishida N, Kaminou T et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am. J. Roentgenol. 2005 184 : 1340 1346.
9. Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc. Intervent. Radiol. 1997 20 : 120 124.
10. Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J. Vasc. Interv. Radiol. 2001 12 : 327 336.
11. Kato T, Uematsu T, Nishigaki Y, Sugihara J, Tomita E, Moriwaki H. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Intern. Med. 2001 40 : 688 691.
12. Akahane T, Iwasaki T, Kobayashi N et al. Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration. Am. J. Gastroenterol. 1997 92 : 1026 1030.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973 60 : 646 649.
14. The Japan Society for Portal Hypertension and Esophago-Gastric Varices. The General Rules for Study of Portal Hypertension, 1st edn.
15. Child CG, Turcotte JG. Surgery and portal hypertension. Major. Probl. Clin. Surg. 1964 1 : 1 85.
16. Kim T, Shijo H, Kokawa H et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997 25 : 307 312.
17. Shimoda R, Horiuchi K, Hagiwara S et al. Short-term complications of retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts. Abdom. Imaging. 2005 30 : 306 313.
18. Hashizume M, Kitano S, Yamaga H Sugimachi K. Haptoglobin to protect against renal damage from ethanolamine oleate sclerosant. Lancet 1988 2 : 340 341.
19. Takuma Y, Nouso K, Makino Y, Saito S, Shiratori Y. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis. Clin. Gastroenterol. Hepatol. 2005 3 : 1245 1252.
20. Ohnishi K, Sato S, Saito M et al. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am. J. Gastroenterol. 1986 81 : 450 455.
21. Nakano R, Iwao T, Oho K, Toyonaga S, Tanikawa K. Splanchnic hemodynamic pattern and liver function in patients with cirrhosis and esophageal or gastric varices. Am. J. Gastroenterol. 1997 92 : 2085 2089.
22. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin. Sci. 1961 21 : 43 57.
23. Keiding S. Hepatic clearance and liver blood flow. J. Hepatol. 1987 4 : 393 398.
24. Miyamoto Y, Oho K, Kumamoto M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. J. Gastroenterol. Hepatol. 2003 18 : 934 942.
25. Cardoso JE, Gautreau C, Jeyaraj PR et al. Augmentation of portal blood flow improves function of human cirrhotic liver. Hepatology 1994 19 : 375 380.
26. Wood AJ, Villeneuve JP, Branch RA, Rogers LW, Shand DG. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology 1979 76 : 1358 1362.
27. Kawasaki S, Imamura H, Bandai Y, Sanjo K, Idezuki Y. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 1992 102 : 1351 1355.
28. Richter GM, Noeldge G, Palmaz JC et al. Transjugular intrahepatic portacaval stent shunt: preliminary clinical results. Radiology 1990 174 : 1027 1030.
29. Ring EJ, Lake JR, Roberts JP et al. Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann. Intern. Med. 1992 116 : 304 309.
30. Jalan R, Gooday R, O'Carroll RE, Redhead DN, Elton RA, Hayes PC. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt. J. Hepatol. 1995 23 : 697 705.
31. Bar F, Battista S, Garello E et al. Short-term effects of transjugular intrahepatic portosystemic shunt (TIPS) on functional liver plasma flow in patients with advanced cirrhosis. Liver 1998 18 : 245 250.
32. Baron A, Gulberg V, Sauter G, Waggershauser T, Reiser M, Gerbes AL. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests. Hepatogastroenterology 1998 45 : 2315 2321.
33. Rossle MSM, Ochs A. Liver function and blood flow before and after TIPS (Abstract). In AASLD, USA, 1993.
34. Sanyal AJ, Freedman AM, Luketic VA et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997 112 : 889 898.
35. Rodriguez-Laiz JM, Banares R, Echenagusia A et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig. Dis. Sci. 1995 40 : 2121 2127.
36. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 1999 29 : 632 639.
37. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967 2 : 1051 1056.
38. Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J. Hepatol. 1989 8 : 107 114.
39. Gentile S, Loguercio C, Marmo R, Carbone L, Del Vecchio Blanco C. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes. Res. Clin. Pract. 1993 22 : 37 44.
40. Kruszynska YT, Ghatei MA, Bloom SR, McIntyre N. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. Hepatology 1995 21 : 933 941.
41. Siegel EG, Seidenstucker A, Gallwitz B et al. Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1. J. Endocrinol. 2000 164 : 13 9.
42. Johnson DG, Alberti KG, Faber OK, Binder C. Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion? Lancet 1977 1 : 10 3.
43. Petrides AS, Groop LC, Riely CA, DeFronzo RA. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis. J. Clin. Invest. 1991 88 : 561 570.
44. Letiexhe MR, Scheen AJ, Gerard PL et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J. Clin. Endocrinol. Metab. 1993 77 : 1263 1268.
45. Kaser S, Foger B, Waldenberger P et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J. Hepatol. 2000 33 : 902 906.
46. Tanabe N, Ishii M, Sato Y et al. Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis. Dig. Dis. Sci. 2000 45 : 581 586.
47. Nishida T, Tsuji S, Tsujii M et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am. J. Gastroenterol. 2006 101 : 70 5.
48. Shiomi S, Kuroki T, Ueda T et al. Relationship between endotoxin antibody levels and portal systemic shunt evaluated by per-rectal portal scintigraphy. J. Gastroenterol. Hepatol. 1994 9 : 138 142.
49. Nolte W, Schindler CG, Figulla HR et al. Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt. J. Hepatol. 2001 34 : 818 824.